A collaborative research group – led by researchers at Cleveland Clinic – published findings that indicate a one-time injection immediately after spinal cord injury can limit pain for an extended period of time.
Fibronectin – a protein that exists naturally in humans – supports the survival, growth and communication of neurons in the brain and spinal cord. The researchers discovered, through testing in an animal model, that an injection of fibronectin into the spinal cord activates specific signaling pathways and results in pain-curbing effects.
"We are very pleased with the results from the fibronectin injection," said Ching-Yi Lin, Ph.D., a researcher in the Department of Neurosciences in Cleveland Clinic's Lerner Research Institute. "Perhaps this will signal a change in pain management after spinal cord injury."
Previous research has shown that spinal cord injury increases the permeability of the blood-spinal cord barrier, causing chronic pain due to exposure of the spinal cord to inflammatory cells. Pain is a particularly important problem after spinal cord injury since the type of pain that ensues after a spinal cord injury is considered even more debilitating than the paralysis itself.
The findings were published in the December issue of the Journal of Neurotrauma and were presented at the annual meeting of Society of Neuroscience. This is a collaborative project between Lin and Yu-Shang Lee, Ph.D., both of the Department of Neurosciences in Cleveland Clinic's Lerner Research Institute; Vernon Lin, M.D., Ph.D., Department of Physical Medicine and Rehabilitation, Cleveland Clinic; and Jerry Silver, Ph.D., Department of Neurosciences, Case Western Reserve University.
While the exact mechanisms underlying the possible fibronectin connection to the relief of chronic pain are not clear yet, results show that fibronectin not only maintained the integrity of the blood-spinal cord barrier but also suppressed the inflammatory response significantly over an eight-month period. Researchers found that fibronectin reversed spinal cord injury-induced decreases in serotonin, a neurotransmitter that plays an important role in pain perception.
The next stage of the study is to test the delayed fibronectin treatment on the inhibition of chronic pain after spinal cord injury, which is more clinically relevant. There is an indication that this treatment also works at later time points.
About Cleveland Clinic
Celebrating its 90th anniversary, Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. It was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S.News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey. About 2,800 full-time salaried physicians and researchers and 11,000 nurses represent 120 medical specialties and subspecialties. Cleveland Clinic Health System includes a main campus near downtown Cleveland, eight community hospitals and 16 Family Health Centers in Northeast Ohio, Cleveland Clinic Florida, the Lou Ruvo Center for Brain Health in Las Vegas, Cleveland Clinic Canada, and opening in 2013, Cleveland Clinic Abu Dhabi. In 2010, there were 4 million visits throughout the Cleveland Clinic health system and 155,000 hospital admissions. Patients came for treatment from every state and from more than 100 countries. Visit us at http://www.clevelandclinic.org/. Follow us at http://www.twitter.com/
Dan Doron | EurekAlert!
Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences